


# STRATEGIC NON-CLINICAL EVALUATION FOR INNOVATIVE CANCER THERAPEUTICS

2018. 6. 29 Fri 12:30-17:30

Venue \_ Grand Auditorium (B1F, Asan Institute for Life Sciences)



Time	Program	Lecturer
12:30-13:20	Registration	
13:20-13:30	Welcome address	<b>Chong Jai Kim, M.D., Ph.D.</b> Chairman, Asan Institute for Life Sciences, Asan Medical Center
<b>[Session 1] Non-clinical evaluation and new drug development</b>		
<b>Yong Man Kim, M.D., Ph.D.</b> Vice-director, Center for Cancer Advancing Therapeutics (CACT), Asan Medical Center		
13:30-14:10	Non-clinical development of Axl/Mer RTK inhibitor as a cancer immunotherapy	<b>Ki Yean Nam, Ph.D.</b> CEO, Qurient Co., Ltd.
14:10-14:50	Development of mutant-selective EGFR-TKIs	<b>Jin Kyung Rho, Ph.D.</b> Professor, Asan Institute for Life Sciences, Asan Medical Center
14:50-15:30	Preclinical development and IND GO/NO-GO decision in anti-cancer drugs	<b>Sung Chun Kim, Ph.D.</b> CSO, Korea Drug Development Fund
15:30-15:50	Break	
<b>[Session 2] Translation of toxicology from in vitro to animal, and to human</b>		
<b>Woo-Chan Son, Ph.D.</b> Director, Center for Non-clinical Development (CND), Asan Medical Center		
15:50-16:20	In vitro cardiotoxicity evaluation for MoA identification	<b>Ki-Suk Kim, Ph.D.</b> Principal Research Scientist, Korea Institute of Toxicology
16:20-16:50	Alternative developmental toxicity test with embryonic stem cells	<b>Eui-Bae Jeung, Ph.D.</b> Professor, Chungbuk National University
16:50-17:20	3D reconstructed human tissues for alternative to animal test	<b>Kyung-Min Lim, Ph.D.</b> Professor, Ewha Womans University
17:20-17:30	Closing remarks	<b>Eun Kyung Choi, M.D., Ph.D.</b> Director, Center for Advancing Cancer Therapeutics(CACT), Asan Medical Center



※ Venue \_ Grand Auditorium (B1F, Asan Institute for Life Sciences)



**Pre-registration**

<https://goo.gl/forms/waQgYawUtACWv20m2>

HOST



SPONSOR

